Early stage clinical trials find experimental vaccine VSV-ZEBOV is safe and promotes antibody response in all 40 adult recipients according to the National Institutes of Health (NIH) and Walter Reed Army Institute of Research (WRAIR). Some recipients experience fever, but except in one case, the fever abates within 24 hours of vaccination. Volunteers are being enrolled in Liberia for the second phase of the trial. Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), states
Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.